Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisotumab Vedotin Monotherapy and Combinations in Recurrent or Stage IVB Cervical Cancer
NCT03786081Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Feb 2019
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of tisotumab vedotin in Cervical Cancer (CC) (8 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities at 21 days and Objective Response Rate at 2 years. Started Feb 2019; status: terminated.
02
Drugs
tisotumab vedotin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03786081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03786081.